Virological and immunological outcomes of elvitegravir-based regimen in a treatment-naïve HIV-2-infected Patient

AIDS

Volumn 28, Issue 15, 2014, Pages 2329-2331

  Zheng, Yue ^a   Lambert, Christine ^a   Arendt, Vic ^a,b   Seguin Devauxa, Carole ^a  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; COBICISTAT; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; RALTEGRAVIR; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; QUINOLONE DERIVATIVE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD; CASE REPORT; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; TIME; TREATMENT OUTCOME; VIROLOGY;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-2; HUMANS; MALE; MIDDLE AGED; QUINOLONES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84924189068     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000414     Document Type: Letter

References (18)

1. Menendez-Arias L, Alvarez M. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. Antiviral Res 2014; 102:70-86.
2. Peterson K, Ruelle J, Vekemans M, Siegal FP, Deayton JR, Colebunders R. The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series. Antivir Ther 2012; 17:1097-1100.
3. Wandeler G, Furrer H, Rauch A. Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2- infected patient. AIDS 2011; 25:2306-2308.
4. Armstrong-James D, Stebbing J, Scourfield A, Smit E, Ferns B, Pillay D, et al. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res 2010; 86:224-226.
5. Damond F, Lariven S, Roquebert B, Males S, Peytavin G, Morau G, et al. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 2008; 22:665-666.
6. Francisci D, Martinelli L, Weimer LE, Zazzi M, Floridia M, Masini G, et al. HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: Which salvage regimen? Clin Drug Investig 2011; 31:345-349.
7. Clumeck N, Molina JM, Henry K, Gathe J, Rockstroh JK, DeJesus E, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs. ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results. J Acquir Immune Defic Syndr 2014; 65:e121-e124.
8. Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, Dejesus E, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results. J Acquir Immune Defic Syndr 2014; 65: e118-120.
9. Ruelle J, Mukadi BK, Schutten M, Goubau P. Quantitative realtime PCR on Lightcycler for the detection of human immunodeficiency virus type 2 (HIV-2). J Virol Methods 2004; 117:67- 74.
10. Bercoff DP, Triqueneaux P, Lambert C, Oumar AA, Ternes AM, Dao S, et al. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology 2010; 7:98.
11. Andreatta K, Miller MD, White KL. HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro. J Acquir Immune Defic Syndr 2013; 62:367-374.
12. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57-65.
13. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82:764-774.
14. Geretti AM, Armenia D, Ceccherini-Silberstein F. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis 2012; 25:677-686.
15. Shimura K, Kodama EN. Elvitegravir: A new HIV integrase inhibitor. Antivir Chem Chemother 2009; 20:79-85.
16. Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- And/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014; 210:354-362.
17. Llibre JM, Clotet B. Once-daily single-tablet regimens: A long and winding road to excellence in antiretroviral treatment. AIDS Rev 2012; 14:168-178.
18. Peterson K, Jallow S, Rowland-Jones SL, de Silva TI. Antiretroviral therapy for HIV-2 infection: recommendations for management in low-resource settings. AIDS Res Treat 2011; 2011:463704.